Document:

<PAGE>

                            PATENT LICENSE AGREEMENT

            Effective on the 19th day of March, 1998, by and between:

                            THE UNIVERSITY OF CHICAGO

                     OPERATOR OF ARGONNE NATIONAL LABORATORY
        UNDER ITS U.S. DEPARTMENT OF ENERGY CONTRACT NO. W-31-109-ENG-38

                                        &

                          PACKARD INSTRUMENT CO., INC.

<PAGE>

This Agreement is between the University of Chicago as Operator of Argonne
National Laboratory under its U.S. Department of Energy (DOE) Contract No.
W-31-109-ENG-38 (hereinafter "Licensor") and Packard Instrument Co., Inc., a
corporation organized and existing under the laws of the State of Delaware with
its principal office at 800 Research Parkway, Meriden, CT 06450 (hereinafter
"Licensee").

1.     BACKGROUND

1.1 Licensor, under the above identified DOE contract has a contractual
arrangement with the Engelhardt Institute of Molecular Biology, Russian Academy
of Sciences, Moscow, Russia under a Memorandum of Understanding dated December
8, 1994 and a subcontract identified as ANL Subcontract No. 943352403. Pursuant
to said Memorandum of Understanding and Subcontract and existing laws of the
United States, Licensor has acquired rights in and to certain inventions
identified in Exhibit A which is attached and incorporated herein.

1.2 Licensor, under the above identified DOE contract, has conceived or first
reduced to practice certain inventions identified in Exhibit A. Pursuant to the
terms of said DOE Contract and existing laws of the United States, Licensor has
acquired certain rights in and to these inventions.

1.3 The inventions described in Article 1.1 and 1.2 above and identified in
Exhibit A which is attached and incorporated herein are hereinafter collectively
referred to as "Background Inventions."

1.4 Licensee has an established commercial position in the drug discovery,
genomic research and biomedical market segments. Licensee markets a wide array
of imagers for the detection of samples on microchips and provides robotic
liquid handling equipment to effect DNA extraction, DNA purification, DNA
amplification (PCR) and sequence template preparation. Licensee wishes to
enhance its commercial position in DNA chip technology and, to effect this, is
entering into collaborative research agreement with Licensor and Motorola, Inc.,
Schaumburg, Illinois, identified as CRADA C9701902. The parties recognize that
Licensor may generate "Subject Inventions" under said CRADA C9701902 and acquire
rights thereto pursuant to the terms of said CRADA, said DOE Contract and
existing laws of the United States.

Licensee desires to acquire rights in and to said Background Inventions and
Licensor's Subject Inventions under CRADA C9701902.

Licensor is willing to grant rights in and to said Background Inventions and
Licensor's Subject Inventions under CRADA C9701902 so that the inventions may be
developed and used to the fullest extent for the benefit of Engelhardt Institute
of Molecular Biology, the benefit of the U.S. Economy and the general public.

2.     DEFINITIONS

2.1 "Licensed Background Patents" shall mean the U.S. patents for inventions
identified and listed in Exhibit A. Such patents shall include all patents of
addition, reissues, reexaminations or extensions of the foregoing provided the
Licensor is the owner thereof or has the right to

<PAGE>

sublicense. Further, such patent applications shall include any continuations,
continuations-in-part and divisions provided the Licensor is the owner thereof
or has the right to sublicense.

2.2 "Licensed Subject-Invention Patents" shall mean the patents issuing on the
Subject Inventions of Licensor under said CRADA C9701902 pursuant to Articles
XVIC and XVIF thereof.

2.3 "Licensed Patents" shall mean any Licensed Background Patents and/or
Licensed Subject-Invention Patents.

2.4 "Licensed Products" shall mean any and all products made, used, or sold by
the Licensee within the scope of one or more claims of Licensed Patents.

2.5 "Licensed Method" is any method, procedure or process whose use or practice
is within the scope of any claim of Licensed Patents.

2.6 "Licensee Affiliate" is defined as any entity in which Licensee, now or in
the future, owns or controls, directly or indirectly, greater than forty percent
(40%) of the stock carrying the right to vote for or appoint directors or
property or equity right in the entity. It further includes BioSignal, Inc.,
1744 William Street, Montreal, QC Canada H3J1R4 provided Licensee has and
maintains a nineteen and one half percentage (19.5%) interest right therein.

2.7 "Gross Sales of Licensed Products" shall mean [* * *]. In the case of
Licensed Products used or transferred internally or incorporated into another
product that does not infringe a Licensed Patent, Gross Sales of Licensed
Products shall mean the fair market value of Licensed Products as if they
were sold to an unrelated third party in similar quantities.

2.8 "Licensed Service" shall mean any service offered or performed by Licensee
wherein a Licensed Method is used or practiced other than to produce a Licensed
Product.

2.9 "Gross Sales of Licensed Services" shall mean [* * *]. In the case of
Licensed Services provided internally, Gross Sales of Licensed Services shall
mean the fair market value of Licensed Services as if they were provided to
an unrelated third party under similar circumstances.

2.10 "Life Science Research Field of Use" is defined in Exhibit E which is
attached and incorporated herein.

2.11 "Clinical Diagnostics Field of Use" is defined in Exhibit F which is
attached and incorporated herein.

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                      -2-
<PAGE>

3.    GRANTS

3.1

      (a) Subject to the terms and conditions of this Agreement, Licensor hereby
grants to Licensee and each Licensee Affiliate in the United States the
nonexclusive right and license, to make, use, and sell Licensed Products and
practice the Licensed Method embodying said Licensed Patents. The nonexclusive
license to Licensee shall include the right to grant sublicenses pursuant to
Article 5 of the same scope in all fields.

            However, it is expressly agreed and understood that the
aforedescribed right to Licensee to grant sublicenses pursuant to Article 5 does
not extend to Licensed Subject-Invention Patents for which Licensee has not
requested U.S. rights pursuant to Article XVC of CRADA C9701902. No right to
sublicense is granted to Licensee for Licensed Subject-Invention Patents for
which Licensee has not requested U.S. rights.

      (b) Subject to the terms and conditions of this Agreement with respect to
Licensed Subject-Invention Patents to which Licensee has requested U.S. rights
pursuant to Article XVC of CRADA C9701902, Licensor hereby grants to Licensee
and each Licensee Affiliate in the United States a limited-exclusive right and
license, with the right to sublicense pursuant to Article 5, to make, use, and
sell Licensed Products and practice the Licensed Methods embodying said Licensed
Subject-Invention Patents in the Life Science Research Field of Use as defined
in Exhibit E. A limited-exclusive license to Licensee of paragraph 3.1(b) of
this Article is subject to a nonexclusive license in the Life Science Research
Field of Use of Exhibit E with the right to sublicense that Licensor may grant
to Motorola, Inc. pursuant to the terms of CRADA C9701902 and a license
agreement associated therewith.

            Subject to the terms and conditions of this Agreement with respect
to Licensed Subject-Invention Patents to which Licensee has requested U.S.
rights pursuant to Article XVC of CRADA C9701902, Licensor hereby grants to
Licensee and each Licensee Affiliate in the United States a nonexclusive right
and license, with the right to sublicense pursuant to Article 5, to make, use,
and sell Licensed Products and practice the Licensed Methods embodying said
Licensed Subject-Invention Patents in the Clinical Diagnostics Field of Use as
defined in Exhibit F. The nonexclusive license to Licensee of paragraph 3.1(b)
of this Article is subject to a limited-exclusive license in the Clinical
Diagnostics Field of Use of Exhibit F with the right to sublicense that Licensor
may grant to Motorola, Inc. pursuant to the terms of CRADA C9701902 and a
license agreement associated therewith.

      (c) Subject to the terms and conditions of this Agreement, Licensor hereby
grants to Licensee and each Licensee Affiliate in each foreign country in which
Licensee has requested rights and in which a patent application has been filed
in accordance with Articles XV and XVI of CRADA C9701902, the nonexclusive right
and license, to make use and sell Licensed Products and practice the Licensed
Methods embodying said Licensed Subject-Invention Patents. The nonexclusive
license to Licensee shall include the right to grant sublicenses pursuant to
Article 5 of the same scope in all fields.

                                      -3-
<PAGE>

      (d) Subject to the terms and conditions of this Agreement, Licensor hereby
grants to Licensee and each Licensee Affiliate, in each foreign country in which
Licensee has requested rights and in which a patent application has been filed
in accordance with Articles XV and XVI of CRADA C9701902, the limited-exclusive
right and license, with the right to sublicense pursuant to Article 5, to make
use and sell Licensed Products and practice the Licensed Methods embodying said
Licensed Subject-Invention Patents in the Life Science Research Field of Use as
defined in Exhibit E. The limited-exclusive license to Licensee of paragraph
3.1(d) of this Article is subject to a nonexclusive license in the Life Science
Research Field of Use of Exhibit E with the right to sublicense that Licensor
may grant to Motorola, Inc. pursuant to the terms of CRADA C9701902 and a
license agreement associated therewith.

            Subject to the terms and conditions of this Agreement, Licensor
hereby grants to Licensee and each Licensee Affiliate, in each foreign country
in which Licensee has requested rights and in which a patent application has
been filed in accordance with Articles XV and XVI of CRADA C9701902, a
nonexclusive right and license, with the right to sublicense pursuant to Article
5, to make use and sell Licensed Products and practice the Licensed Methods
embodying said Licensed Subject-Invention Patents in the Clinical Diagnostics
Field of Use as defined in Exhibit F. The nonexclusive license to Licensee of
paragraph 3.1(d) of this Article is subject to a limited-exclusive license in
the Clinical Diagnostics Field of Use of Exhibit F with the right to sublicense
that Licensor may grant to Motorola, Inc. pursuant to the terms of CRADA
C9701902 and a license agreement associated therewith.

3.2 The license and right granted in Article 3.1 is subject to the following
U.S. Government rights:

THE U.S. GOVERNMENT HAS A PAID-UP, ROYALTY-FREE, NON-TRANSFERABLE, WORLDWIDE,
IRREVOCABLE LICENSE FOR GOVERNMENT USE TO PRACTICE OR HAVE PRACTICED BY OR ON
BEHALF OF THE U.S. GOVERNMENT THE LICENSED PATENTS. THE U.S. GOVERNMENT HAS
CERTAIN OTHER RIGHTS UNDER 35 USC 200 ET SEQ. AND APPLICABLE REGULATIONS.

3.3

      (a) Licensee may, within [* * *] after the last party executed this
Agreement, request in writing foreign rights in and to a Licensed Background
Patent. Such request shall identify each country in which Licensee requests
license rights.

      (b) Licensor, to the extent it has the right at the time of Licensee's
written request and to the extent that no patent application has been filed
thereon in the identified country, will cause to be filed on the Licensed
Background Patent, a patent application in each country identified by Licensee.

      (c) Licensee agrees that it shall be responsible for and pay, as directed
by Licensor, for all external costs associated with the drafting, filing,
prosecuting, issuance and maintenance fees of each Licensed Background Patent
for which a patent application is filed in each country at Licensee's request
pursuant to paragraphs 3.3 (a) and (b) above of this Article.

      (d) Licensor shall provide copies of documents to be filed, filed and
received in the prosecution of patent applications filed by Licensor pursuant to
paragraph 3.3 (b) above on each

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                      -4-
<PAGE>

Licensed Background Patent and shall afford Licensee an opportunity to comment
thereon. It is expressly understood and agreed that Licensor shall control the
prosecution of patent applications on Licensed Background Patent patent
applications, taking into account any comments provided by Licensee.

      (e) Licensee agrees to pay its costs obligated under this Article within
thirty (30) days after receipt of billing. Failure to pay such costs by Licensee
shall terminate any license to Licensee granted under this Agreement to any
patent application covered by such costs.

      (f) Licensor, to the extent that it has the right at the time of
Licensee's written request of paragraph 3.3(a), agrees to grant a nonexclusive
license to Licensee in each such patent application filed at Licensee's expense
in each country identified by Licensee, with the right to sublicense pursuant to
Article 5, to make use and sell Licensed Products and practice the Licensed
Method embodying said Licensed Background Patent.

      (g) It is anticipated by the parties that Licensor shall enter into an
arrangement with Motorola, Inc., Schaumburg, IL, wherein Motorola, Inc. may
request nonexclusive foreign license rights in and to Licensed Background
Patents. Licensor agrees that to the extent that such rights are granted to
Motorola, Inc. in and to a patent application on a Licensed Background Patent in
a country for which Licensee has an obligation to pay the costs thereon pursuant
to paragraph 3.3 (c) of this Article, Licensee's obligation thereto shall be
reduced to fifty percent (50%) of such costs.

      (h) Licensor agrees that, if Licensor grants any license to a third
party in and to a patent application or patents on a Licensed Background
Patent in a country for which Licensee has an obligation to pay all the costs
thereon pursuant to paragraph 3.3(c) of this Article (other than to the U.S.
Government or Motorola, Inc. under a collaborative research agreement with
Licensor), Licensor agrees to pay Licensee [* * *] of the gross royalties from
such license attributable to said patent application until a sum equal to[* * *]
times the amount paid by Licensee as costs under this Article 3.3 is
attained. For patent applications or patents on a Licensed Background Patent
wherein Licensee's obligation to pay the costs therefor is [* * *]of such
costs, Licensee's share of the gross royalties attributable to such patent
application or patent shall be [* * *] of the gross royalties until a sum equal
to [* * *] the amount paid by Licensee as costs under this Article 3.3 is
attained.

4.    U.S. COMPETITIVENESS

Licensee agrees that any Licensed Product(s) for use or sale in the United
States shall be manufactured substantially in the United States. Further,
Licensee agrees that if Licensee is a CRADA Participant with Licensor, then the
U.S. Competitiveness terms and conditions of said CRADA shall apply to Licensed
Subject-Invention Patents under this License Agreement.

5.    SUBLICENSES

5.1   Licensee may grant sublicenses only under the following conditions:

      (a)   Licensed Products sold or used in the U.S. will be substantially
            manufactured in the U.S., and

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                      -5-
<PAGE>

      (b)   Significant economic and technical benefits will flow to the U.S. as
            a result of the sublicense agreement.

If these conditions cannot be met, then the Licensee must obtain written
approval from the Licensor before granting a sublicense.

5.2 Any sublicenses that the Licensee grants to a third party must include all
the applicable rights and obligations due the Licensor that are contained in
this Agreement. Licensee will not sublicense at rates lower than those set forth
in Exhibit C, paragraphs B and C, without prior written consent of Licensor. The
sublicenses granted under this Agreement are subject to the license to the U.S.
Government and the rights reserved by the Licensor.

5.3 Licensee will provide the Licensor with a copy of each sublicense entered
into with a third party within thirty (30) days of execution. All sublicense
royalties due the Licensor pursuant to Exhibit C, Paragraph D from the sale of
Licensed Products and the practice of Licensed Methods by a Sublicensee shall be
paid to Licensor by Licensee.

5.4 Licensee will pay Licensor the amounts due from sublicensees and deliver all
reports due the Licensor from sublicensees according to the schedule set forth
in Article 7 (Records and Reports).

5.5 If this Agreement is terminated for any reason or abated pursuant to Article
8.2, Licensor will automatically succeed to all rights of Licensee arising from
sublicenses granted under this Agreement. Any sublicensee who is not in default
of the terms and conditions of its sublicensee agreement with Licensee may make
a written request to continue such sublicense agreement as a license agreement
with the Licensor, which request will not be unreasonably withheld.

6.    ROYALTIES AND COMMERCIALIZATION PLAN

6.1 In consideration of the rights and licenses granted herein, Licensee agrees
to the provisions of Exhibit B and Exhibit C attached hereto and hereby
incorporated into this Agreement.

6.2 No royalties shall be owed on any Licensed Product(s) produced or any
Licensed Method practiced for or under any Federal governmental agency contract
pursuant to the DOE nonexclusive license for Federal governmental purposes but
only to the extent the Federal government received a discount on Licensed
Product or Licensed Service sales which discount is equivalent to or greater
than the amount of any such royalty that would otherwise be due.

6.3 No royalties shall be owed on any Licensed Product(s) produced or Licensed
Method practiced for or on behalf of Motorola, Inc. to the extent that Motorola,
Inc. has a license thereto granted by Licensor and is obligated to pay royalties
thereon to Licensor. However, such must be reported pursuant to Article 7.

6.4 Upon termination of this Agreement for any reason whatsoever, any royalties
that remain unpaid shall be promptly reported and paid to Licensor within thirty
(30) days of any such termination.

                                      -6-
<PAGE>

6.5 Licensed Products are considered sold when invoiced, if not invoiced, when
delivered to a third party. If any patent covering Licensed Products expires, or
if the license terminates, then all shipments made on or before the date of
expiration or termination that have not been billed are considered sold and
subject to royalty. Royalties paid on Licensed Products which are not accepted
by the customer are credited to Licensee.

6.6 Licensed Services are considered sold when invoiced, if not invoiced, when
provided to a third party.

6.7 When the Gross Sales of Licensed Products and Services by Licensee attain
[***], Licensee may request in writing that the royalty terms of this license
as set forth in Appendix C be renegotiated. Licensor and Licensee agree, upon
receipt by Licensor of such written request, to renegotiate such royalty
terms in good faith and that such terms shall reflect customary Government
and industry licensing practices at that time.

7.    RECORDS AND REPORTS

7.1 Licensee agrees to keep adequate and sufficiently detailed records of
Licensed Product(s) and Licensed Services to enable royalties payable hereunder
to be determined and to provide such records for inspection at Licensee's
facilities in the U.S. by authorized representatives of Licensor at any time
upon reasonable advance notice during the regular business hours of Licensee.
Licensee agrees that any extant additional records of Licensee, as Licensor may
reasonably determine are necessary to verify the above records, shall also be
provided to Licensor for inspection at Licensee's facilities in the U.S.

7.2 Licensor will pay the costs incurred by its representatives to examine
the Licensee's books and records. If there is any error in the royalty
accounting of more than [* * *] of the total royalties due for any year or
[* * *]whichever is greater, then Licensee will pay the reasonable costs
incurred for the Licensor's examination.

7.3 Within thirty (30) calendar days after the close of each calendar year
during the term of this Agreement (i.e. January 31), Licensee will furnish
Licensor a written report providing: (a) the aggregate amount of all sales in
U.S. Dollars during the preceding calendar year period of Licensed Product(s)
(if none, Licensee will so indicate) and (b) the aggregate amount of royalties
due in U.S. Dollars for the preceding calendar year period pursuant to the
provisions hereof. (See Exhibit D part B)

7.4 Licensee will pay Licensor royalties due hereunder on a quarterly basis for
quarters ending March 3l, June 30, September 30 and December 3l. Such quarterly
payments shall be paid to Licensor no later than thirty (30) days following each
quarterly period. (See Exhibit D part C)

7.5 Should Licensee fail to make any payment to Licensor within the time period
prescribed for such payment, then the unpaid amount shall bear interest at the
rate of one and one-half percent (1.5%) per month or, if less, the greatest
amount permitted by law, from the date when payment was due until payment in
full, with interest, is made.

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                      -7-
<PAGE>

8.    DUE DILIGENCE

8.1 Licensee will proceed diligently to develop, manufacture, sell, and provide
Licensed Products and Licensed Services. Licensee will market Licensed Products
or Licensed Services diligently within a reasonable time after this Agreement is
executed. Licensee must demonstrate a continuing effort to market Licensed
Products and Licensed Services following Licensee's first offer of Licensed
Products and Licensed Services for sale.

8.2 If Licensee is unable to perform the schedule and conditions set forth in
Exhibit B, and the diligence of Article 8.1 above, as its sole and exclusive
remedy for such inability to perform, Licensor may abate Licensee's license
of Article 3.1 to a nonexclusive license with no right to sublicense with the
royalties of Exhibit C applicable thereto, except that the minimum annual
royalties of Exhibit C shall be [* * *] per year for the year 2001 and each
calendar year thereafter.

9.    TECHNICAL ASSISTANCE

Licensor agrees, upon the written request of Licensee and within the policies
and rules of the Department of Energy then in effect, to assist Licensee in
seeking necessary DOE approvals for Licensor to provide technical assistance to
Licensee at Licensor's facilities under appropriate agreements. The cost of such
technical assistance shall be paid by the Licensee.

10.   INFRINGEMENT BY THIRD PARTIES

10.1 If Licensee learns of the infringement of any patent licensed under this
Agreement, Licensee will inform Licensor in writing within thirty (30) days and
provide all known evidence of the infringement. Licensee will not contact the
potential infringer concerning the infringement without prior written approval
of the Licensor. The parties will use their best efforts to cooperate with each
other to terminate the infringement without litigation.

10.2 Licensee may request in writing that Licensor take legal action against
infringement of a Licensed Patent. This request must include reasonable evidence
of the infringement and damages to Licensee.

10.3 Within one hundred and eighty (180) days of Licensee's request, if the
infringement continues, the Licensor will:

      (a)   commence suit on its own account; or

      (b)   agree to bring suit jointly with Licensee; or

      (c)   notify Licensee that the Licensor will not bring suit and agrees to
            the extent Licensee has a limited-exclusive license in the infringed
            patent and standing in a court of competent jurisdiction, Licensee
            may bring suit on its own account.

10.4 If Licensee elects to bring suit in accordance with this Article, the
Licensor may join such suit later at the Licensor's expense.

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.
                                      -8-
<PAGE>

10.5 Legal action brought by one party will be at the expense of that party, who
will be entitled to all recoveries from that suit. If Licensor and Licensee
bring a joint legal action, the parties will share the expenses and recoveries
in proportion to the costs incurred by each party.

10.6 Each party will cooperate with the other in litigation proceedings brought
under this Agreement, but at the expense of the party bringing suit, except that
each party may be represented by counsel of its choice in any suit brought by
the other party.

11.   REPRESENTATIONS AND WARRANTIES

11.1 Licensor represents and warranties that Licensor has the right to grant the
rights, licenses, and privileges granted herein.

11.2 Nothing in this Agreement will be interpreted as:

      (a) A warranty or representation by the Licensor as to the validity or
scope of any of the Licensor's rights in Licensed Patents; or

      (b) A warranty or representation that anything made, used, sold, or
otherwise disposed of under any license granted in this Agreement is or will be
free from infringement of patents or copyrights of third parties; or

      (c) Any obligation to bring suit against a third party for patent or
copyright infringement; or

      (d) Conferring by implication, estoppel, or otherwise any license or
rights under any patents of the Licensor other than Licensed Patents as defined
in this Agreement, regardless of whether such patents are dominant or
subordinate to Licensed Patents; or

      (e) An obligation to furnish any know-how or improvements not specifically
provided in this Agreement.

11.3 Licensor represents and warranties that Licensor has no knowledge of any
claims of infringement filed against Licensor for practicing the Licensed
Patents.

12.   EXPORT CONTROL

LICENSEE ACKNOWLEDGES THAT THE EXPORT OF ANY PRODUCTS AND/OR TECHNICAL DATA FROM
THE UNITED STATES MAY REQUIRE SOME FORM OF EXPORT CONTROL LICENSE FROM THE U.S.
GOVERNMENT. FAILURE TO OBTAIN ANY REQUIRED EXPORT LICENSES BY LICENSEE MAY
RESULT IN LICENSEE SUBJECTING ITSELF TO CRIMINAL LIABILITY UNDER U.S. LAWS.

13.   DISCLAIMER

NEITHER LICENSOR, THE DOE, NOR PERSONS ACTING ON THEIR BEHALF MAKE ANY WARRANTY,
EXPRESS OR IMPLIED: (1) WITH RESPECT TO THE MERCHANTABILITY, ACCURACY,
COMPLETENESS, OR USEFULNESS OF ANY

                                       -9-
<PAGE>

SERVICES, MATERIALS, OR INFORMATION FURNISHED HEREUNDER; (2) THAT THE USE OF ANY
SUCH SERVICES, MATERIALS, OR INFORMATION WILL NOT INFRINGE PRIVATELY OWNED
RIGHTS; (3) THAT THE SERVICES, MATERIALS, OR INFORMATION FURNISHED HEREUNDER
WILL NOT RESULT IN INJURY OR DAMAGE WHEN USED FOR ANY PURPOSE; OR (4) THAT THE
SERVICES, MATERIALS, OR INFORMATION FURNISHED HEREUNDER WILL ACCOMPLISH THE
INTENDED RESULTS OR ARE SAFE FOR ANY PURPOSE, INCLUDING THE INTENDED OR
PARTICULAR PURPOSE. FURTHERMORE, LICENSOR AND THE DOE HEREBY SPECIFICALLY
DISCLAIM ANY AND ALL WARRANTIES, EXPRESS OR IMPLIED, FOR ANY PRODUCTS
MANUFACTURED, USED, OR SOLD BY LICENSEE. NEITHER LICENSOR NOR THE DOE SHALL BE
LIABLE FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES IN ANY EVENT.

14.   PRODUCT LIABILITY

Except for any liability resulting from any negligent act or omission of the
U.S. Government or the Licensor, Licensee indemnities the U.S. Government and
the Licensor, and their officers, employees, and agents, for all damages, costs,
and expenses, including attorneys' fees, arising from personal injury or
property damage to third parties occurring as a result of the commercialization
and utilization of the Licensed Patents by Licensee, including but not limited
to, the making, using, selling, or exporting of products, processes, or services
derived therefrom. This indemnification shall include, but not be limited to,
indemnification for any product liability resulting from the commercialization
and utilization or the Licensed Patents by Licensee. The indemnity set forth in
this Paragraph 14 shall apply only if Licensee shall have been informed as soon
and as completely as practical by the Licensor and/or the U.S. Government of the
action alleging such claim and shall have been given an opportunity, to the
maximum extent afforded by applicable laws, rules, or regulations, to
participate in and control its defense, and the Licensor and/or the U.S.
Government shall have provided reasonably available information and reasonable
assistance requested by Licensee. No settlement for which Licensee shall be
responsible shall be made without Licensee's consent unless required by final
decree of a court of competent jurisdiction.

15.   TERM OF AGREEMENT AND EARLY TERMINATION OR ABATEMENT

15.1 Unless previously terminated by operation of law or by acts of the Parties
under this Agreement, this Agreement is binding upon the date of execution by
the last signing party ("Effective Date") and will run to and terminate upon the
expiration of the last-to-expire issued patent covered by Licensed Patents.

15.2 A party shall have the right to terminate this Agreement (without judicial
resolution) upon notice to the other party after a breach of any material
provision by the other party has gone uncorrected for sixty (60) days after the
other party has been notified of such breach by the terminating party.

15.3 [* * *]

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                      -10-
<PAGE>

[* * *] If agreement is not reached within ninety (90) days after the issuance
of such injunctive relief, Licensee may terminate this license prospectively
without charge by written notice to Licensor. Such termination shall be
effective upon receipt by Licensor of said notice.

15.4 Licensee may terminate this License Agreement prospectively by giving
written notice to Licensor any time subsequent to November 1, 2000. Such
termination by Licensee shall be subject to a termination fee payable by
Licensee to Licensor of [* * *] payable thirty (30) days after the effective
date of such termination. Further, such termination shall be effective thirty
(30) days from the date of delivery of such notice and all of Licensee's
rights under this Agreement shall cease as of that date.

15.5 Licensor agrees that the minimum royalty payments of Exhibit C, Paragraph
E.1. shall be abated a pro rata amount of any delay in completion of task 2B in
the Scope of Work of CRADA C9701902.

15.6 Commencing January 1, 2001, Licensee, upon six (6) month written notice
to Licensor, may prospectively abate Licensee's license of Article 3.1 to a
nonexclusive license with no right to sublicense with the royalties of
Exhibit C applicable thereto except that the minimum annual royalty of
Exhibit C shall be [* * *] per calendar year thereafter. Further, such
abatement shall be subject to Licensee paying Licensor a license abatement
fee of [* * *] payable thirty (30) days after the effective date of such
abatement.

16.   ASSIGNABILITY

The Parties agree that Licensor, at its sole discretion, may immediately
terminate this Agreement upon any attempt by Licensee to transfer its interest
in whole or in part in this Agreement to any other party without the written
permission of the Licensor, unless such transfer is to an acquirer of all or
substantially all of Licensee's business and that such acquirer shall agree to
the U.S. Competitiveness clause of this license and CRADA C9701902 as though it
were a Participant therein. With respect to a transfer to a successor to
Licensee's business, Licensor's permission shall be required, if acquirer is not
a U.S. corporation.

17.   RIGHTS OF PARTIES AFTER TERMINATION

17.1 Neither party shall be relieved of any obligation or liability under this
Agreement arising from any act or omission committed prior to the effective date
of termination. All licensed rights granted under this agreement shall terminate
as of the effective date of any termination.

17.2 From and after any termination of this Agreement, Licensee shall have the
right to sell any Licensed Products that Licensee had already manufactured prior
to termination, provided

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                      -11-
<PAGE>

that all royalties and reports required hereinabove shall be submitted to
Licensor. Licensee will provide the Licensor with a written inventory of all
Licensed Products in stock within thirty (30) days of the effective date of
termination by either party. All sales of such inventoried Licensed Products are
subject to the terms of this Agreement.

17.3 Except as provided in Article 8.2, the rights and remedies granted herein,
and any other rights or remedies which the parties may have, either at law or in
equity, are cumulative and not exclusive of others. On any termination, Licensee
shall duly account to Licensor and transfer to them all rights to which Licensor
may be entitled under this Agreement.

18.   FORCE MAJEURE

No failure or omission by Licensor or by Licensee in the performance of any
obligation under this Agreement shall be deemed a breach of this Agreement or
create any liability if the same shall arise from acts of God; acts or omissions
of any government or agency thereof, compliance with rules, regulations, or
orders of any governmental authority; fire; storm; flood; earthquake; accident;
acts of the public enemy; war; rebellion; insurrection; riot; sabotage;
invasion; quarantine; restriction; or failures or delays in transportation.

19.   USE OF NAMES, TRADENAMES, AND TRADEMARKS

Nothing contained in this License Agreement shall be construed as conferring any
right to use in advertising, publicity, or other promotional activities any
name, tradename, trademark, or other designation of any Licensor or Licensee or
of the U.S. Department of Energy or the U.S. Government, or any of their
employees or officers, and any contraction, abbreviation, or simulation of any
of the foregoing.

20.   NOTICES

20.1 All notices and reports shall be addressed to the parties hereto as
follows:

        If to Licensor:
        Argonne National Laboratory                 Facsimile No.
        9700 S. Cass Avenue                         708/252-4517
        Argonne, IL  60439                          Verify No.
        ATTN:  R. Jeffrey Geouque                   708/252-3023
        OCF-PRO/201

        If to Licensee:
        Packard Instrument Co., Inc.                Facsimile No.
        800 Research Parkway                        203/238-7593
        Meriden, CT  06450                          Verify No.
        ATTN:  Staf van Cauter                      203/639-2202

20.2 Any notice, report or any other communication required or permitted to be
given by one party to the other party by this Agreement shall be in writing and
either (a) served personally on

                                      -12-
<PAGE>

the other party, (b) sent by express, registered or certified first-class mail,
postage prepaid, addressed to the other party at its address as indicated above,
or to such other address as the addressee shall have previously furnished to the
other party by proper notice, (c) delivered by commercial courier to the other
party, or (d) sent by facsimile to the other party at its facsimile number
indicated above or to such other facsimile number as the party shall have
previously furnished to the other party by proper notice, with machine
confirmation of transmission. Such notice shall be effective when received by
the receiving party.

21.   NON-ABATEMENT OF ROYALTIES

Licensor and Licensee acknowledge that certain of the Licensed Patents may
expire prior to the conclusion of the term of this Agreement; however, Licensor
and Licensee agree that the royalty rates provided for hereinabove shall be
uniform and undiminished, except as otherwise provided pursuant to this
Agreement.

22.   WAIVERS

22.1 No provision of this Agreement is deemed waived and no breach excused
unless such waiver or consent is made in writing and signed by the party to have
waived or consented.

22.2 Failure on the part of any party to exercise or enforce any right under
this Agreement will not be a waiver of any right, or operate to bar the
enforcement or exercise of the right at any time thereafter.

23.   LICENSE PATENT MARKING

Licensee agrees to affix appropriate markings of the applicable Licensor
Licensed Patents upon or in association with Licensee's Licensed Products or
Services.

24.   ENTIRE AGREEMENTS AND MODIFICATIONS

It is expressly understood and agreed by the parties hereto that this instrument
and CRADA C9701902 contains the entire agreement between the parties with
respect to the subject matter hereof and that all prior representations,
warranties, or agreements relating hereto have been merged into this document
and CRADA C9701902 and are thus superseded in totality by this Agreement and
CRADA C9701902. This Agreement may be amended or modified only by a written
instrument signed by the duly authorized representatives of the parties.

25.   HEADINGS

The headings for the sections set forth in this Agreement are strictly for the
convenience of the parties hereto and shall not be used in any way to restrict
the meaning or interpretation of the substantive language of this Agreement.

26.   DISPUTES AND GOVERNING LAWS

26.1 The Parties will attempt to jointly resolve any disputes arising from this
Agreement. Such joint resolution may include non-binding arbitration. If the
Parties are unable to resolve a

                                      -13-
<PAGE>

dispute within a reasonable time, then either party may commence proceedings in
a court of competent jurisdiction. United States federal law will govern this
Agreement to the extent that there is such law. To the extent there is no
applicable federal law, this Agreement and performance hereunder will be
governed by the laws of the State of Illinois, USA, without regard to the
state's conflict of laws provisions.

26.2 If any provisions of this Agreement are held to be invalid, illegal, or
unenforceable in any respect, that invalidity, illegality, or unenforceability
will not affect any other provisions of the Agreement. This Agreement will be
construed as if the invalid, illegal, or unenforceable revision were never in
this Agreement.

26.3 The Licensor will release information concerning this Agreement if required
by law.

27.   THIRD PARTY LICENSES

27.1 Licensor agrees that to the extent that it grants a nonexclusive license to
a third party to Licensed Patents identified in Exhibit A of the same scope
granted to Licensee, such shall be at no more favored terms than those granted
to Licensee in Exhibit C.

27.2 To the extent that Licensee or Motorola, Inc. declines to commercialize the
intellectual property of a third party under reasonable terms and conditions in
the Clinical Diagnostics Field of Use of Exhibit F, Licensee agrees to
nonexclusively sublicense such third party under reasonable terms and conditions
to the extent that such sublicense, as necessary, provides substantial benefit
to the public health or safety.

                                      -14-
<PAGE>

            IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be duly executed in their respective names by their duly authorized
representatives.

"Licensor"

By:  /s/ Dennis E. Bugielski

Name:  (typed) Dennis E. Bugielski

Title:   Manager, ANL Procurement

Date:

"Licensee"

By:  /s/  Richard T. McKernan
          --------------------

Name:  (typed)
                --------------------

Title:
        --------------------

Date:  3/19/98

                                      -15-<PAGE>

--------------------------------------------------------------------------------

                          STRATEGIC MARKETING AGREEMENT

                                  by and among

                        Agencourt Bioscience Corporation
                            (a Delaware corporation)

                                       and

                           Packard BioScience Company
                            (a Delaware corporation)

                                October 11, 2000

--------------------------------------------------------------------------------

<PAGE>

                          STRATEGIC MARKETING AGREEMENT

      This STRATEGIC MARKETING AGREEMENT (this "Agreement") is entered into as
of October 11, 2000 (the "Effective Date"), by and between Agencourt Bioscience
Corporation, a Delaware corporation ("Agencourt"), and Packard BioScience
Company, a Delaware corporation ("Packard" and together with Agencourt, the
"Parties").

      WHEREAS, Agencourt has developed certain proprietary products and
technology for high-throughput Nucleic Acid purification;

      WHEREAS, Packard is the manufacturer of automated laboratory testing
equipment and certain consumables for the Life Sciences market; and

      WHEREAS, Agencourt and Packard desire to enter into a strategic marketing
alliance (the "Marketing Alliance") whereby each Party agrees to promote the
sales of the other Party's products to its customers and clients;

      NOW THEREFORE, for and in consideration of the covenants, conditions, and
undertakings hereinafter set forth, and other good and valuable consideration,
the sufficiency and receipt of which is hereby acknowledged, it is agreed by and
between the Parties as follows:

1.    DEFINITIONS

      1.1 "$"- has the meaning set forth in Section 13.6.

      1.2 "Affiliate" means, with respect to any Person, any other Person that
directly or indirectly controls or is controlled by or under common control with
such Person. For the purposes of this definition, "control," when used with
respect to any Person, means the possession, direct or indirect, of the power to
direct or cause the direction of the management and policies of such Person,
whether through the ownership of voting securities, by contract or otherwise;
and the terms of "affiliated," "controlling" and "controlled" have meanings
correlative to the foregoing.

      1.3 "Agencourt" has the meaning set forth in the preamble.

      1.4 "Agencourt Customers" means any Third Party to whom Agencourt has sold
or granted the right to use the Agencourt Products.

      1.5 "Agencourt Products" means the packaged reagent products as set forth
on Schedule A hereto, and any derivatives, improvements or enhancements directly
related thereto which are created or developed by Agencourt.

      1.6 "Agreement" has the meaning set forth in the preamble.

<PAGE>

      1.7 "Alternative Equipment" means any equipment that an Agencourt Customer
owns or proposes to purchase that is not produced by Packard.

      1.8 "Association" has the meaning set forth in Section 13.18.

      1.9 "Breaching Party" has the meaning set forth in Section 7.5.

      1.10 "Capital Transaction" means the offer, sale, disposition, grant or
option to purchase of any equity or equity-equivalent Securities of Agencourt,
including the issuance of any debt or other instrument at any time over the life
thereof convertible into or exchangeable for Common Stock, or any other
transaction intended to be exempt or not subject to registration under the
Securities Act.

      1.11 "Change of Control" means with respect to any Person (i) the sale of
all or substantially all of the assets of such Person, (ii) a sale of all or
substantially all of the equity securities of such Person to a Third Party,
(iii) the merger or consolidation of such Person with a Third Party, except if
the voting securities of such Person outstanding immediately before the merger
or consolidation would continue to represent (either by remaining outstanding or
by being converted into voting securities of the surviving entity) at least a
majority of the combined voting power of the voting securities of such Person or
such surviving entity outstanding immediately after such merger or
consolidation; or (iv) the liquidation or dissolution of such Person.

      1.12 "Change of Management" means the voluntary or involuntary removal of
            [* * *].

      1.13 "Common Stock" has the meaning set forth in Section 5.1.

      1.14 "Confidential Information" has the meaning set forth in Section 8.1.

      1.15 "Customers" means the Agencourt Customers and the Packard Customers.

      1.16 "Delivery Schedule" has the meaning set forth in Section 3.1.

      1.17 "Demonstration Equipment" has the meaning set forth in Section 3.3.

      1.18 [* * *].

      1.19 "DNA" means deoxyribonucleic acid.

      1.20 "Dollars" has the meaning set forth in Section 13.6.

      1.21 "Effective Date" has the meaning set forth in the preamble.

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                       2
<PAGE>

      1.22 "Equipment" has the meaning set forth in Section 3.4.

      1.23 "Finder's Fee" has the meaning set forth in Section 2.5.

      1.24 "First Round" has the meaning set forth in Section 5.1.

      1.25 "Genome" means the genetic code of various organisms, including, but
not limited to, Human, Mouse, Chimpanzee, Acorn Worm, Neurospora, Dog, Horse,
ZebraFish, Tetraodon, Pufferfish, Corn, Wheat, Loblolly Pine.

      1.26 [* * *].

      1.27 "Indemnified Party" has the meaning set forth in Section 10.2.

      1.28 "Indemnifying Party" has the meaning set forth in Section 10.2.

      1.29 "Indemnitees" has the meaning set forth in Section 10.1.

      1.30 "Intellectual Property" has the meaning set forth in Section 8.2.

      1.31 "Losses" has the meaning set forth in Section 10.1.

      1.32 "Marketing Alliance" has the meaning set forth in the recitals.

      1.33 "Net Sales" means, for each Product sold by a Party or any Affiliate
of a Party to a Third Party (other than an Affiliate), [* * *].

      1.34 "Nucleic Acid" means both DNA and RNA.

      1.35 "Packard" has the meaning set forth in the preamble.

      1.36 "Packard Customers" means any Third Party to whom the Packard has
granted the right to use the Packard Products.

      1.37 "Packard Maintenance Agreement" means the Maintenance Agreement set
forth on Exhibit IV.

      1.38 "Packard Products" means the products set forth on Schedule B hereto,
and any derivatives, improvements or enhancements directly related thereto which
are created or developed by Packard.

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                       3
<PAGE>

      1.39 "Packard Terms and Conditions" means Packard's standard terms and
conditions as set forth on Exhibit III.

      1.40 "Parties" has the meaning set forth in the preamble.

      1.41 "PCR" means polymerase chain reaction.

      1.42 "Person" means any individual, corporation, partnership, trust,
incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or political subdivision
thereof) or other entity of any kind.

      1.43 "Plasmid Vectors" has the meaning set forth in Schedule A hereto.

      1.44 "Products" means the Agencourt Products and the Packard Products.

      1.45 "Purchased Equipment" has the meaning set forth in Section 3.1.

      1.46 "Research Collaborators" means the 20 individual laboratories
approved by Packard in its reasonable discretion with whom Agencourt has a
research collaboration agreement. Agencourt will identify such Persons to
Packard in writing [* * *].

      1.47 "Qualified Public Offering" means a fully underwritten, firm
commitment public offering, including a firm commitment underwriting performed
by the Dutch auction method, pursuant to an effective registration statement
filed under the Securities Act covering the offer and sale by the Corporation of
shares of its Common Stock in which the aggregate price paid by the public for
such shares shall equal or exceed [* * *].

      1.48 "Report" has the meaning set forth in Section 2.6.

      1.49 "Restrictive Covenants" has the meaning set forth in Section 7.5.

      1.50 "RNA" means ribonucleic acid.

      1.51 "Second Round" means [* * *].

      1.52 "Securities" means any and all shares of, or any securities
convertible or exercisable into shares of, capital stock of Agencourt.

      1.53 "Securities Act" means the Securities Act of 1933, as amended.

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                       4
<PAGE>

      1.54 "Stockholders Agreement" means the Stockholders Agreement, dated as
of July 5, 2000, among Agencourt and certain holders of its Securities, as may
be amended, modified or supplemented from time to time.

      1.55 "Strategic Partner" means [* * *].

      1.56 "Strategic Transaction" means any relationship in which Agencourt
issues to a Strategic Partner (including, but not limited to, an acquisition or
joint venture, but shall not include a Capital Transaction) Securities, in a
single transaction or a series of transactions, which in the aggregate equal
more than 5% of the total issued and outstanding Securities as determined at the
time of such issuance and taking into account such issuance.

      1.57 "Subscription Agreement" has the meaning set forth in Section 5.1.

      1.58 "Temporary Equipment" has the meaning set forth in Section 3.4.

      1.59 "Third Party" means any Person other than Agencourt or Packard, or an
Affiliate of either of them.

      1.60 "Transaction Notice" has the meaning set forth in Section 6.1.

      1.61 "Warrant" has the meaning set forth in Section 5.2.

2.    MARKETING ALLIANCE

      2.1 Marketing and Promotion.

            (a) The Parties shall use commercially reasonable efforts to engage
in co-marketing and co-promotion activities in connection with the Agencourt
Products and the Packard Products. Neither Party shall enter into an agreement
with any Third Party that would prohibit it from marketing and promoting the
other Party's Products.

            (b) Packard [* * *]. in trade journals, including, but not limited
to, (i) Genetic Engineering News, (ii) Nature, (iii) Science, (iv) Nature
Biotech, and (v) Genome Research.

            c) The Parties shall use commercially reasonable efforts to prepare
a mutually agreeable marketing and promotion plan within [* * *] of the
date

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                       5
<PAGE>

hereof. Such plan shall include, at a minimum, (i) the number of advertisements
that the Parties shall purchase in accordance with Section 2.1; (ii) the number
of issues of each trade journal in which such advertisements will appear; (iii)
the design, layout, artwork and copy for each advertisement; and (iv) the
appropriate allocation of expenses for the marketing, promotion, and advertising
efforts described in this Section 2.1.

      2.2 [* * *].

      2.3 Sales Leads and Mailing Lists. Each Party shall mutually cooperate
with the other Party to share information in promoting and furthering the sale
of their respective Products and obtaining new Customers.

      2.4 Reimbursement of Expenses. Neither Party shall be obligated to
reimburse the other Party, in whole or in part, for any expense which such other
Party incurred, unless the Parties mutually agree to such reimbursement, in
writing, prior to the incurring of such an expense.

      2.5 Finder's Fee. Packard shall pay to Agencourt a finder's fees (the
"Finder's Fee") equal to [* * *] of Net Sales on any Packard Product related to
Nucleic Acid purification sold to [* * *] during the term of this Agreement.

      2.6 Reports and Payment. Packard shall deliver to Agencourt, within 60
days after the end of each calendar quarter (such calendar quarter shall end on
March 31, June 30, September 30, and December 31), a written accounting of
Finder's Fees (the

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                       6
<PAGE>

"Report"), including quantities and monetary amounts of sales of each Packard
Product and the amount of the Finder's Fee payments due to Agencourt for such
calendar quarter. Packard shall, simultaneously with the delivery of each
Report, tender to Agencourt the total Finder's Fee shown to be due thereon.

      2.7 Audit Rights. Packard shall permit Agencourt or its representatives to
have access, no more than once in each calendar year during the term of this
Agreement and twice during the three calendar years following the termination
hereof, during regular business hours and upon reasonable notice, to its records
and books solely to the extent necessary to determine the appropriateness of all
amounts payable hereunder. If such examination reveals that such amounts have
been understated for any calendar year, Packard shall promptly pay the amount of
any verified underpayment; provided that if such examination was not conducted
by an independent accountant, Packard shall have the right to engage an
independent accountant at Packard's expense and reasonably acceptable to
Agencourt, to verify the results of such examination. If such independent
accountant determines that the amount of the underpayment is incorrect, such
amount shall be adjusted accordingly and, to the extent Packard has underpaid
amounts owed to Agencourt, shall be promptly paid by Packard. If, however, such
examination reveals that such amounts have been overstated for any calendar
year, Agencourt shall promptly refund the amount of any overpayment to Packard.

3.    PURCHASE AND DEMONSTRATION OF PACKARD EQUIPMENT

      3.1 Purchased Equipment. Packard hereby agrees to sell, assign, transfer
and deliver to Agencourt, and Agencourt hereby agrees to purchase from Packard,
subject to the Packard Terms and Conditions, the Packard Products listed on
Schedule C (the "Purchased Equipment"). Packard shall deliver the Purchased
Equipment to Agencourt in accordance with the delivery schedule listed on
Schedule C (the "Delivery Schedule").

      3.2 Payment Schedule. Agencourt shall pay to Packard the aggregate
purchase price of [* * *] for the Purchased Equipment, in accordance with the
Packard Terms and Conditions and the following payment schedule:

            (a) [* * *] on the Effective Date; and

            (b) [* * *] upon delivery of the Purchased Equipment.

      3.3 Demonstration Equipment. Packard shall deliver to Agencourt, in
accordance with the delivery schedule listed on Schedule D, the Packard Products
listed on Schedule D (the "Demonstration Equipment"). In accordance with the
time periods set forth on Schedule D, the Demonstration Equipment shall be
returned to Packard in good working conditions, reasonable wear and tear
excepted. Packard shall retain all right and title to the Demonstration
Equipment.

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                       7
<PAGE>

      3.4 Temporary Equipment. Packard shall deliver to Agencourt, no later than
[* * *], the Packard Products listed on Schedule E (the "Temporary
Equipment" and, collectively with the Purchased Equipment and the Demonstration
Equipment, the "Equipment"). In accordance with the time periods set forth on
Schedule E, the Temporary Equipment shall be returned to Packard in good working
conditions, reasonable wear and tear excepted. Packard shall retain all right
and title to the Temporary Equipment.

      3.5 Training and Support. Packard shall provide Agencourt with all
necessary and appropriate training and support regarding the use of the
Equipment in accordance with Packard's standard policies and procedures.

      3.6 Repair and Maintenance of Equipment. Subject to the terms and
conditions of the Packard Maintenance Agreement, Packard shall repair and
maintain the Equipment, [* * *] from the date such Equipment is delivered to
Agencourt. With respect to any Equipment, Agencourt shall have the option to
renew the Packard Maintenance Agreement for up to [* * *] at Packard's then
current rate for the Packard Maintenance Agreement for such Equipment.

      3.7 Rights in the Equipment. Packard covenants and warrants that the
Equipment shall be delivered free and clear of all liens and encumbrances.

4.    SERVICING AND MAINTENANCE

      4.1 Unless otherwise agreed by the Parties, all sales of Packard Products
made by Packard to Third Parties identified by Agencourt shall be made on
substantially the same terms and conditions as the Packard Terms and Conditions
and Packard shall offer to such Third Parties the option, at Packard's
then-current fee, to enter into maintenance agreement on substantially the same
terms and conditions as Packard makes available to similarly situated Customers.

      4.2 Unless otherwise agreed by the Parties, all sales of Agencourt
Products made by Agencourt to Third Parties identified by Packard shall be made
on substantially the same terms and conditions as Agencourt's standard terms and
conditions.

5.    PURCHASE OF COMMON STOCK AND WARRANTS

      5.1 Common Stock. In connection with Agencourt's next round of financing
that is expected to be consummated on or about September 30, 2000 (the "First
Round"), Packard or its Affiliates shall purchase shares of Agencourt common
stock, par value $0.0001 (the "Common Stock") from Agencourt at [* * *] per
share, for a total purchase price of approximately [* * *], in accordance
with the terms and conditions of the subscription booklet attached hereto as
Exhibit I (the "Subscription Agreement").

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                       8
<PAGE>

      5.2 Warrant. On the Effective Date of this Agreement, Packard or its
Affiliates shall purchase from Agencourt for a total purchase price of [* * *],
and Agencourt shall issue to Packard, a warrant (the "Warrant"), substantially
in the form attached herein as Exhibit II, registered in the name of Packard, or
in such other name as Packard shall designate.

6.    [* * *].

7.    RESTRICTIVE COVENANTS

      7.1 Non-Competition. If, during the term of this Agreement, a Party,
directly or indirectly, develops, manufactures, markets, sells or otherwise
distributes any products that are competitive with the Products of the other
Party, then the other Party shall have

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                       9
<PAGE>

the right to immediately terminate this Agreement and its obligations hereunder;
provided, however, that each Party may market or promote its Products or the
products of other Persons if such marketing and promotion is conducted in
accordance with the provisions of Section 2.

      7.2 Non-Solicitation. Except as otherwise provided herein, during the term
of this Agreement, each Party agrees that neither it nor any of its divisions or
operating groups that directly participates in or is directly responsible for
the development or commercialization of the Products pursuant to this Agreement
shall, directly or indirectly (a) recruit, solicit or induce any employee of the
other Party or any of its Affiliates to terminate his or her employment with
such other Party or in any way interfere with the relationship between the other
Party and any employee thereof; (b) induce or attempt to induce any customer,
supplier, licensee, licensor or other business relation of the other Party or
any of its Affiliates to cease doing business with the other Party or such
Affiliate; or (c) make any disparaging statements or communications about the
other Party or any of its Affiliates. Generalized solicitations, such as job
postings and newspaper advertisements, shall not be considered to be
"recruiting," "inducing," or "soliciting" under this Section 7.2.

      7.3 Geographic Scope. The restrictions contained in this Section 7 shall
extend to all geographic areas, whether in the United States or outside of the
United States where the Party seeking the enforcement of this Section 7 has, at
any time during the term of this Agreement, offered any products, processes or
services.

      7.4 Substitution of Terms. If an arbitrator or court shall hold that the
duration, scope or area restrictions stated herein are unreasonable under
circumstances then existing, the Parties agree that the maximum duration, scope
or area reasonable under such circumstances shall be substituted for the stated
duration, scope or area and that the arbitrator or court shall be allowed to
revise the restrictions contained herein to cover the maximum period, scope and
area permitted by law.

      7.5 Rights and Remedies. If a Party breaches, or threatens to commit a
breach (the "Breaching Party") of, any of the covenants set forth in this
Section 7 (the "Restrictive Covenants"), the other Party shall have the
following rights and remedies, each of which rights and remedies shall be
independent of the others and severally enforceable, and each of which is in
addition to, and not in lieu of, any other rights and remedies available to the
other Party at law or in equity, including the right and remedy to have the
Restrictive Covenants specifically enforced by any court of competent
jurisdiction, it being agreed that any breach or threatened breach of the
Restrictive Covenants would cause irreparable injury to the other Party and that
money damages would not provide an adequate remedy to the other Party.

                                       10
<PAGE>

8.    CONFIDENTIALITY

      8.1 Confidential Information.

            (a) The Parties agree that all information, know-how, trade,
scientific, technical or non-technical data, samples, materials, manuals,
conclusions, operating and testing procedures, formulas, formulations, business
plans, marketing and sales information, reports, drawings, or plans, including,
but not limited to, information specifically relating to the marketing and sales
of the Products, or information relating to the business affairs or finances of
the Parties or their Affiliates or of any suppliers, agents, distributors,
licensees or customers of the Parties, when it comes into the possession of the
other Party, whether disclosed or provided in oral, written (including but not
limited to electronic, facsimile, paper or other means), graphic, photographic
or any other form, and, that a Party knows or reasonably should have known is
the confidential information of the other Party, shall be deemed confidential
information ("Confidential Information").

            (b) Without limiting the foregoing, information disclosed in
accordance with Sections 2.1, 2.2., 2.3, 2.6 and 2.7 shall be deemed
"Confidential Information" for purposes of this Agreement.

            (c) For purposes of this Agreement, the definition of "Confidential
Information" shall be deemed to exclude information:

                  (i) which is provided to Third Parties to the extent necessary
to use the Products;

                  (ii) which can be shown by written documentation to have been
known by the recipient prior to receipt from the other;

                  (iii) which is public or lawfully becomes generally available
to the public through no fault of the recipient;

                  (iv) which is lawfully acquired from a Third Party without
being made subject to an obligation of confidence by the Third Party;

                  (v) which by mutual agreement is released from its
confidential status;

                  (vi) which is required to be disclosed under any statutory,
regulatory or judicial requirement, including, but not limited to, any filing
with the Securities Exchange Commission and in that event, confidentiality will
be preserved and protected to the extent possible; additionally, notice will be
provided to the other Party prior to any such disclosure.

                                       11
<PAGE>

            (d) Each Party shall hold Confidential Information of the other
Party in strict confidence and disclose it only on a need-to-know basis to
Affiliates, subcontractors and employees of the Parties, who are under a written
obligation to maintain the confidentiality of the information.

            (e) Each Party shall use Confidential Information of the other Party
only in connection with the activities described in this Agreement.

      8.2 Ownership of Data; No License. Each Party acknowledges that the other
Party possesses certain inventions, processes, know-how, trade secrets,
improvements, patents, copyrights, other intellectual properties and proprietary
rights and other assets, including but not limited to analytical methods,
procedures and techniques, procedure manuals, personnel data, financial
information, computer technical expertise and software, which have been
independently developed by the other Party and which relate to its business or
operations or its Products (collectively "Intellectual Property"). It is
expressly agreed that neither Party transfers to the other Party by operation of
this Agreement any Intellectual Property. All data and information generated or
derived by a Party as the result of services performed by such Party under this
Agreement shall be and remain the exclusive property of such Party. Any
Intellectual Property that may evolve from the data and information as the
result of services performed by a Party under this Agreement shall belong to
such Party.

      8.3 Survival. Unless otherwise specifically provided in this Agreement,
the obligations of the Parties under this Section 8 shall survive the
termination or expiration of this Agreement for a period of [* * *].

9.    REPRESENTATIONS AND WARRANTIES

      Each Party represents and warrants to the other that:

      9.1 Corporate Power. It is duly organized and validly existing under
existing under the laws of its state or country of incorporation, and has full
corporate power and authority to enter into this Agreement and to carry out the
provisions hereof.

      9.2 Due Authorization. It is duly authorized to execute and deliver this
Agreement and to perform its obligations hereunder, and the Person or Persons
executing this Agreement on its behalf has been duly authorized to do so by all
requisite corporate action.

      9.3 Binding Agreement. This Agreement is legally binding upon it and
enforceable in accordance with its terms. The execution, delivery and
performance of this Agreement by it does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a Party or by which
it may be bound, nor violate any

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                       12
<PAGE>

material law or regulation of any court, governmental body or administrative or
other agency having jurisdiction over it.

      9.4 Grant of Rights; Maintenance of Agreements. It has not, and will not
during the term of this Agreement, grant any right to any Third Party which
would conflict with the rights granted to the other Party hereunder or enter any
agreement which would impair its ability to perform its obligations under this
Agreement. It has (or will have at the time performance is due) maintained and
will maintain and keep in full force and effect all agreements necessary to
perform its obligations hereunder.

      9.5 Validity. It is aware of no action, suit or inquiry or investigation
instituted by any governmental agency that questions or threatens the validity
of this Agreement.

      9.6 Conformance with Laws. The Parties agree to undertake all of their
respective obligations under this Agreement in material conformance with all
applicable local, state and federal laws and regulations, as amended. By
entering into this Agreement, it is not the intent of the Parties to enter into
any financial relationship or arrangement prohibited under state or federal
fraud or abuse regulations, nor do the Parties hereto have any belief that the
relationship and compensation arrangement provided in this Agreement is
prohibited. Neither Party shall assert against the other that the compensation
arrangement provided in this Agreement is grounds for voiding the Agreement or
rendering the Agreement unenforceable.

      9.7 Rights in Products. Each Party warrants that, to its knowledge, it
owns, free and clear, the entire right, title and interest in and to any patent
and has obtained any and all required licenses in order to fulfill its
obligations under this Agreement. As of the Effective Date, each Party warrants
and represents that:

            (a) it has no knowledge of the existence of any patent or trademark
owned or controlled by anyone other than such Party or trademark owned or
controlled by anyone other than such Party or an Affiliate which covers the
Party's Products and would prevent the Party from making, using, or selling the
Party's Products or would prevent the Party from promoting or marketing the
Party's Products;

            (b) it is not aware of any patents or trademarks owned by Third
Parties that would be infringed by the promotion or sale of such Party's
Products;

            (c) it is not pursuing any action against any Third Party that such
Party believes infringes its trademark, copyright or patent relating to the
Product of such Party; and

            (d) there are no actions, suits, claims or proceedings pending
against such Party or any of its Affiliates in any court or before any agency,
related to alleged patent, trademark, or copyright infringement in connection
with such Party's Products,

                                       13
<PAGE>

and to the best of such Parties' knowledge, no such actions, suits, claims or
proceedings have been threatened.

During the term of this Agreement, each Party will use diligent efforts not to
diminish the rights granted to the other Party herein, including without
limitation by not committing or permitting any acts or omissions which would
cause the material breach of any agreements between such Party and Third Parties
which provide for intellectual property rights applicable to the development,
manufacture, use or sale of such Party's Product. As of the Effective Date, each
Party is in compliance in all material respects with any such agreements with
Third Parties.

      9.8 No Conflicts. Neither the execution and delivery of this Agreement nor
the consummation or performance of any of the contemplated transactions will,
directly or indirectly, contravene, conflict with or result in a violation or
breach of any provision of, or give any Third Party the right to declare a
default or exercise any remedy under, or to cancel, terminate or modify, any
agreement with a Third Party relating to the Products.

      9.9 Disclosure of Agreement. The Parties shall coordinate efforts
regarding the preparation and distribution of press releases and other public
announcements of this Agreement. Neither Party shall make a public announcement
or otherwise disclose the terms of this Agreement to any Third Party without
giving prior notice to the other Party and receiving no objection, except that
the Parties may without each other's consent disclose (a) the existence of this
Agreement, (b) the identity of the other Party and (c) the general subject
matter of this Agreement. Each Party shall also be permitted to make such
disclosure of the terms of this Agreement as its counsel reasonably determines
is necessary to comply with law, provided that such Party shall use commercially
reasonable efforts to obtain confidential treatment of any such disclosure.

      9.10 No Use of Names or Trademarks. Neither Party will use the other
Party's name in connection with any publication or promotion without the other
Party's prior written consent. Nor shall either Party use the other Party's
corporate or product logo or trademark in any manner without the other Party's
prior written consent.

10.   INDEMNIFICATION; LIMITATION ON LIABILITY

      10.1 Indemnification. Each Party shall indemnify, defend, save, protect,
and hold harmless the other Party, its Affiliates, and its and their respective
directors, officers, employees, and agents ("Indemnitees") against any and all
losses, claims, damages (including special, incidental, indirect, consequential,
or punitive damages awarded in a final court or arbitrator's decision to a Third
Party), liabilities, costs and expenses (including reasonable attorneys fees and
expenses and court costs) (collectively, "Losses") to the extent directly
resulting or arising from any Third Party claims, actions, proceedings,
investigations or litigation relating to or arising from or in connection with:
(a) the design, development, manufacture, sale, distribution or use of the
Party's Products; (b) the breach by the Party of any of its obligations under
this Agreement; (c)

                                       14
<PAGE>

the negligent or wrongful acts or omissions of the Party or any of its
directors, officers, employees or agents; (d) a violation of any law, rule or
regulation by the Party relating to this Agreement; or (e) the infringement or
violation, or alleged infringement or violation by the Party or the Party's
Product of any patents or any copyrights, trademark, trade secret or other
intellectual property rights. Notwithstanding the foregoing, neither Party shall
be required to indemnify the other Party for any Losses to the extent they arise
from the negligent or wrongful acts or omissions of the Indemnitees or the
Indemnitees' breach of its obligations under this Agreement.

      10.2 Procedure. The Party seeking indemnification hereunder (the
"Indemnified Party") shall (a) promptly notify the Party obligated to indemnify
(the "Indemnifying Party") of any Losses for which the Indemnified Party seeks
indemnification; (b) cooperate fully with Indemnifying Party and its legal
representatives in the investigation of any matter the subject of
indemnification; (c) permit the Indemnifying Party full control over the defense
and settlement of any matter the subject of indemnification; provided, however,
that no such matter shall be settled without the prior written consent of the
Indemnified Party, such consent not to be unreasonably withheld; and (d) not
unreasonably withhold its approval of the settlement of any claim, liability or
action by Indemnifying Party covered by this indemnification provision.

      10.3 No Consequential or Punitive Damages. Notwithstanding each Parties'
rights and remedies in equity, neither Party, nor its Affiliates or their
respective directors, officers, employees or agents shall have any liability to
the other Party for any special, incidental, indirect, consequential, or
punitive damages, including, but not limited to the loss of opportunity, use,
revenue or profit, in connection with or arising out of this Agreement, or the
services performed by the Party hereunder, even if such damages were
foreseeable.

      10.4 Insurance. Each Party shall at its own expense obtain and maintain
insurance of a type and amount as may be necessary to protect its interests and
obligations connected with its performance under this Agreement. Neither Party
shall do or omit to do any act, matter or thing which could prejudice or render
voidable any such insurance. Each Party shall, upon request by the other,
provide a certification evidencing the insurance or any renewal. Each Party
shall notify the other Party of any cancellation of or material change in any
such insurance arrangements, if possible, prior to cancellation or material
change, but in any event, as soon as possible.

11.   [* * *].

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                       15
<PAGE>

12.   TERM AND TERMINATION

      12.1 Term. This Agreement shall take effect as of the Effective Date and
shall remain in effect for an initial term of [* * *], unless sooner
terminated in accordance with the provisions of Section 7.1 or this Article 12.

      12.2 Renewal. This Agreement may be renewed for an additional term, upon
the mutual written agreement of the Parties.

      12.3 Material Breach. Either Party may terminate this Agreement by written
notice at any time if the other Party defaults in the performance of any
material obligations under this Agreement. In the event of such default, the
Party declaring the default shall provide the defaulting Party with written
notice setting forth the nature of the default, and the defaulting Party shall
have thirty (30) days to cure the default. If the defaulting Party fails to cure
the default within the foregoing time periods, and provided the default is
continuing, the other Party may terminate this Agreement by written notice to
the defaulting Party, which notice shall be effective upon receipt.

      12.4 Bankruptcy. Either Party may terminate this Agreement by written
notice to the other Party, if the other Party files a petition for bankruptcy,
reorganization or arrangement under any state statute, or makes an assignment
for the benefit of creditors or takes advantage of any insolvency statute or
similar statute, or such filing is made by a Third Party, and such filing is not
withdrawn within sixty (60) days of the filing date, or

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                       16
<PAGE>

if a receiver or trustee is appointed for the property and assets of the Party
and the receivership proceedings are not dismissed within sixty (60) days of
such appointment.

      12.5 Accrued Rights. Termination of the Agreement for whatever reason
shall not affect the accrued rights of either of the Parties, arising under or
out of this Agreement and all provisions that expressly or by implication
survive this Agreement shall remain in full force and effect. Termination of
this Agreement shall not relieve the Parties of any liability which accrued
hereunder prior to the date of such termination nor preclude either Party from
pursuing all rights and remedies it may have hereunder or at law or in equity
with respect to any breach of this Agreement nor prejudice either Party's right
to obtain performance of any obligation.

      12.6 Fees Upon Termination. Upon termination of the Agreement pursuant to
this Article 12 or otherwise, all earned and unpaid fees and other charges
payable under this Agreement shall become immediately due and payable.

      12.7 Return of Materials. At the completion of the services by either of
the Parties or upon termination pursuant to this Article 12, all materials and
all other data owned by the other Party under this Agreement, regardless of the
method of storage or retrieval, shall either be delivered to such other Party in
such form as is then currently in the possession of the Party or disposed of, at
the direction and written request of the other Party unless such materials are
otherwise required to be stored or maintained by the other Party as a matter of
law or regulation. The costs associated with this Section shall be paid by Party
storing or disposing such materials or data, as described in this Section.

      12.8 Survival. The following provisions shall survive any expiration or
termination of this Agreement, and if time periods are specified, for the period
of time specified: Section 2.7, Articles 8-10, Sections 12.5-12.7, and Article
13.

      12.9 Notices. All notices, requests, consents and other communications
hereunder shall be in writing, shall be telecopied or mailed by first class
registered or certified airmail (return receipt requested), postage prepaid, and
shall be deemed given when so telecopied or, if mailed, when received:

            (a)   if to Agencourt to:

                  Agencourt Bioscience Corporation
                  100 Cummings Center
                  Suite 107J
                  Beverly, MA  01915
                  Attention: Chief Executive Officer
                  Facsimile: (978) 867-2601

                                       17
<PAGE>

                  With a copy to:

                  Paul, Hastings, Janofsky & Walker LLP
                  399 Park Avenue
                  Thirty - First Floor
                  New York, NY 10022-4697
                  Attention: John J. Altorelli, Esq.
                  Facsimile: 212-319-4090

                  or to such other person at such other place as Agencourt shall
                  designate to Packard in writing;

            (b)   if to Packard, to:

                  Packard BioScience Company
                  800 Research Parkway
                  Meriden, CT 06450
                  Attention: Chief Financial Officer
                  Facsimile: 203-235-6089

                  With a copy to:

                  Packard BioScience Company
                  800 Research Parkway
                  Meriden, CT 06450
                  Attention: General Counsel
                  Facsimile: 203-235-6089

                  and:

                  Day, Berry & Howard LLP
                  CityPlace I
                  Hartford, CT 06103
                  Attention: Richard D. Harris, Esq.
                  Facsimile: (860) 275-0343

                  or to such other person at such other places as Packard shall
                  designate to Agencourt in writing.

13.   MISCELLANEOUS

      13.1 Entire Agreement and Amendment. This Agreement, and the other
agreements referred to herein between the Parties, set forth the complete, final
and exclusive agreement and all the covenants, promises, agreements, warranties,

                                       18
<PAGE>

representations, conditions and understandings between the Parties hereto and
supersede and terminate all prior agreements and understandings between the
Parties. There are no covenants, promises, agreements, warranties,
representations, conditions or understandings, either oral or written, between
the Parties other than as are set forth herein and therein. No subsequent
alteration, amendment, change or addition to this Agreement or to the Exhibits
hereto, shall be binding upon the Parties unless reduced to writing and signed
by an authorized officer of each Party.

      13.2 Force Majeure. Both Parties shall be excused from the performance of
their obligations under this Agreement to the extent that such performance is
prevented by force majeure and the non-performing Party promptly provides notice
of the prevention to the other Party. Such excuse shall be continued so long as
the condition constituting force majeure continues and the non-performing Party
takes reasonable efforts to remove the condition. For purposes of this
Agreement, force majeure shall include conditions beyond the control of the
Parties, including without limitation, an act of God, voluntary or involuntary
compliance with any regulation, law or order of any government, war, civil
commotion, labor strike or lock-out, epidemic, failure or default of public
utilities or common carriers, destruction of production facilities or materials
by fire, earthquake, storm or like catastrophe; provided, however, the payment
of invoices due and owing hereunder shall not be delayed by the payor because of
a force majeure affecting the payor.

      13.3 Headings. The headings of the various sections of this Agreement have
been inserted for convenience of reference only and shall not be deemed to be
part of this Agreement.

      13.4 Consents Not Unreasonably Withheld or Delayed. Whenever provision is
made in this Agreement for either Party to secure the consent or approval of the
other, that consent or approval shall not unreasonably be withheld or delayed,
and whenever in this Agreement provisions are made for one Party to object to or
disapprove a matter, such objection or disapproval shall not unreasonably be
exercised.

      13.5 Maintenance of Records. Each Party shall keep and maintain all
records required of it by law or regulation or by this Agreement with respect to
the transactions contemplated in this Agreement, and shall make copies of such
records available to the other Party upon request.

      13.6 United States Dollars. References in this Agreement to "Dollars" or
"$" shall mean the legal tender of the United States of America.

      13.7 No Strict Construction. This Agreement has been prepared jointly and
shall not be strictly construed against either Party.

                                       19
<PAGE>

      13.8 Ambiguities. Ambiguities, if any, in this Agreement shall not be
construed against any Party, irrespective of which Party may be deemed to have
authored the ambiguous provision.

      13.9 Assignment. Neither Party may assign or transfer this Agreement or
any rights or obligations hereunder without the prior written consent of the
other Party; provided, however, that either Party may assign this Agreement to a
successor-in-interest without the other Party's consent upon a Change of Control
of such Party, unless the Change of Control has occurred in connection with any
of the following Persons: [* * *]. Any permitted successor-in-interest or
assignee of rights and/or obligations hereunder shall, in a writing to the
other Party, expressly assume performance of such rights and/or obligations.
Any permitted assignment shall be binding on the successors-in-interest of
the assigning Party. Any assignment or attempted assignment by either Party
in violation of the terms of this Section 13.9 shall be null and void and of
no legal effect. This Agreement shall be binding upon and shall inure to the
benefit of each Party's successors-in-interest and permitted assigns.

      13.10 Performance by Affiliates. Obligations under this Agreement may be
performed by Affiliates of Agencourt and of Packard. In the event any such
performance is carried out by Affiliates with the prior consent of the other
Party, each of Agencourt and Packard guarantees performance of this Agreement by
its Affiliates. No Affiliate of a Party may make decisions inconsistent with
this Agreement, amend the terms of this Agreement or act contrary to its terms
in any way.

      13.11 Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

      13.12 Severability. If any one or more of the provisions of this Agreement
is held to be invalid or unenforceable by any court of competent jurisdiction
from which no appeal can be or is taken, the provision shall be considered
severed from this Agreement and shall not serve to invalidate any remaining
provisions hereof. The Parties shall make a good faith effort to replace any
invalid or unenforceable provision with a valid and enforceable one such that
the objectives contemplated by the Parties when entering this Agreement may be
realized.

      13.13 No Waiver. Any delay in enforcing a Party's rights under this
Agreement or any waiver as to a particular default or other matter shall not
constitute a waiver of such Party's rights to the future enforcement of its
rights under this Agreement, except

[* * *] Indicates information omitted pursuant to a request for confidential
treatment and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 under the Securities Exchange Act of 1934,
as amended.

                                       20
<PAGE>

with respect to an express written and signed waiver relating to a particular
matter for a particular period of time.

      13.14 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the Commonwealth of Massachusetts, without giving
effect to the conflict of laws principles thereof.

      13.15 Business Days. If any date for payment or notice under this
Agreement falls on a Saturday, Sunday or bank holiday, then the referenced date
shall move to the first working day following such date, provided that the
calculation of working days are never to include Saturdays, Sundays or bank
holidays and the calculation of days (without reference to "working" days) shall
include Saturdays, Sundays and bank holidays.

      13.16 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original but all of which
together will constitute one and the same instrument. A facsimile, telecopy or
other reproduction of this Agreement may be executed by one or more Parties
hereto, and an executed copy of this Agreement may be delivered by one or more
parties hereto by facsimile or similar instantaneous electronic transmission
device pursuant to which the signature of or on behalf of such Party can be
seen, and such execution and delivery shall be considered valid, binding and
effective for all purposes as of the date first written above. At the request of
any Party hereto, all Parties hereto agree to execute an original of this
Agreement as well as any facsimile, telecopy or other reproduction hereof.

      13.17 Good Faith Negotiations. If after the Effective Date any dispute
arises in connection with this Agreement, with respect to a claim that is not
settled promptly in the ordinary course of business, the Parties shall seek to
resolve any such dispute between them, first, by negotiating promptly with each
other in good faith in face-to-face negotiations. If the Parties are unable to
resolve such dispute between them within twenty (20) business days (or such
period as the Parties shall otherwise agree) through these face-to-face
negotiations, then any such dispute shall be resolved in the manner set forth in
Section 13.18.

      13.18 Arbitration. If the Parties do not resolve a dispute under Section
13.17, the dispute shall be settled by arbitration conducted on a confidential
basis, under the U.S. Arbitration Act, if applicable, and the then current
Commercial Arbitration Rules of the American Arbitration Association (the
"Association") strictly in accordance with the terms of this Agreement and the
substantive Law of the Commonwealth of Massachusetts. The arbitration shall be
conducted at the Association's regional office located in the Boston,
Massachusetts area by one neutral arbitrator. Judgment upon the arbitrator's
award may be entered and enforced in any court of competent jurisdiction.
Neither Party shall institute a proceeding hereunder unless at least 60 days
prior thereto such Party shall have given written notice to the other Party of
its intent to do so. In any award, the arbitrator shall assess the arbitration
costs and expenses, including attorneys'

                                       21
<PAGE>

fees of the Parties, in a manner deemed equitable by the arbitrator, taking into
account the arbitration decision.

      13.19 Waiver of Jury Trial. WITH RESPECT TO ANY DISPUTE ARISING UNDER OR
IN CONNECTION WITH THIS AGREEMENT, WHICH HAS NOT BEEN RESOLVED BY NEGOTIATION AS
PROVIDED HEREIN AND AS TO WHICH LEGAL ACTION NEVERTHELESS OCCURS, EACH PARTY
HEREBY IRREVOCABLY WAIVES ALL RIGHTS IT MAY HAVE TO DEMAND A JURY TRIAL. THIS
WAIVER IS KNOWINGLY, INTENTIONALLY, AND VOLUNTARILY MADE BY EACH PARTY HERETO
AND EACH PARTY ACKNOWLEDGES THAT NONE OF THE OTHER PARTIES NOR ANY PERSON ACTING
ON BEHALF OF THE OTHER PARTIES HAS MADE ANY REPRESENTATION OF FACT TO INDUCE
THIS WAIVER OF TRIAL BY JURY OR IN ANY WAY TO MODIFY OR NULLIFY ITS EFFECT. EACH
PARTY FURTHER ACKNOWLEDGES THAT IT HAS BEEN REPRESENTED OR HAS HAD THE
OPPORTUNITY TO BE REPRESENTED IN THE SIGNING OF THIS AGREEMENT AND IN THE MAKING
OF THIS WAIVER BY INDEPENDENT LEGAL COUNSEL, SELECTED OF ITS OWN FREE WILL, AND
THAT IT HAS HAD THE OPPORTUNITY TO DISCUSS THIS WAIVER WITH COUNSEL. EACH PARTY
FURTHER ACKNOWLEDGES THAT IT HAS READ AND UNDERSTOOD THE MEANING AND
RAMIFICATIONS OF THIS WAIVER PROVISION.

      13.20 No Partnership. The relationship of the Parties hereto shall be that
of independent contractors and neither Party shall have the authority to bind
the other Party. Nothing herein shall be construed to create any partnership,
joint venture, or similar relationship, or to subject the Parties to any implied
duties or obligations respecting the conduct of their affairs which are not
expressly stated herein.

                           [SIGNATURE PAGE TO FOLLOW]

                                       22
<PAGE>

      IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate
originals by their duly authorized officers as of the date and year first above
written.

                        AGENCOURT BIOSCIENCE CORPORATION

                        By: /s/ R. Brian McKernan
                            ----------------------------------------
                            R. Brian McKernan
                            President

                        PACKARD BIOSCIENCE COMPANY

                        By: /s/ Ben D. Kaplan
                            ----------------------------------------
                            Name: Ben D. Kaplan
                            Title: VP & CFO

                [SIGNATURE PAGE TO STRATEGIC MARKETING AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00027-of-00352.parquet"}]]